Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2NSCLC 1Meningeal Carcinomatosis 1Carcinoma 1Brain Neoplasms 1Advanced Non-Small Cell Lung Cancer 1

Interventions

icotinib 2anlotinib 2Drug Therapy 2lorlatinib 1Thalidomide 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × NSCLC × lorlatinib × Clear all
NCT06893354 2025-03-25

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

The First Affiliated Hospital of Guangzhou Medical University

Phase 4 Not yet recruiting
20 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡